NEW YORK, NY — As Breast Cancer Awareness Month unfolds across the globe, a poignant, multicolored glow will descend upon the night sky this October 13. From the towering spires of New York’s One World Trade Center to the historic masonry of Philadelphia City Hall and the distant horizons of Scotland and the Philippines, more than 325 landmarks will be bathed in the signature teal, green, and pink of the metastatic breast cancer (MBC) community.
This massive coordinated illumination marks the annual #LightUpMBC campaign, a global initiative spearheaded by the nonprofit METAvivor Research and Support. The campaign serves as a stark, necessary reminder that while early detection remains a vital conversation in oncology, a significant, often overlooked population—those living with Stage 4, or metastatic, breast cancer—continues to face a terminal diagnosis without a cure.
The Reality of Stage 4: More Than Just a Diagnosis
To understand the urgency behind the #LightUpMBC movement, one must first confront the medical reality of metastatic breast cancer. Unlike early-stage breast cancer, which may be treated with the goal of elimination, MBC occurs when cancer cells migrate from the breast to distant, vital organs—most commonly the bones, liver, lungs, or brain.
Despite this spread, the disease remains classified as breast cancer. It is not a separate entity, but rather a more advanced, systemic form of the original condition. For many, the diagnosis comes as a "de novo" event, meaning they are Stage 4 from the moment they are first identified as having cancer. For others, the disease is a secondary, often devastating, recurrence that emerges months, years, or even decades after an initial, "successful" treatment for earlier-stage breast cancer.
The clinical path for an MBC patient is a grueling marathon of perpetual treatment. Even in cases where medical scans show "no evidence of disease," the underlying condition persists. The therapeutic goal is not eradication, but rather disease management: extending the patient’s life and maintaining a baseline of quality. Because cancer cells are inherently adaptive, they frequently develop resistance to established therapies, forcing patients into a cycle of constant treatment adjustments and medical vigilance.
Chronology of a Movement: From a Single Friend’s Wish to Global Awareness
The genesis of #LightUpMBC is deeply personal. It began with the quiet, earnest hope of Jessica Moore, who, while battling the disease at just 36 years old, expressed a desire to see a single local landmark illuminated to raise awareness for the plight of those living with metastatic cancer.
Following Moore’s passing, her best friend, Laura Inahara, transformed that singular wish into a global crusade. Since its inception, the campaign has evolved into a powerhouse of advocacy and fundraising.
- 2017: The movement achieves its first milestone as New Hampshire’s Memorial Bridge becomes the inaugural landmark to shine in honor of MBC.
- 2021–2025: The campaign experiences exponential growth, expanding from a domestic U.S. effort to an international phenomenon, capturing the attention of major world monuments and bridge authorities.
- October 13, 2026: The campaign marks its most expansive year yet, encompassing 325 landmarks across all 50 U.S. states, 20 countries, and 195 cities.
What began as a localized tribute has now raised over $2.7 million for critical research, proving that a singular, grief-stricken spark can ignite a worldwide movement for systemic change.
Supporting Data: The Urgent Need for Research
The statistics underpinning the need for #LightUpMBC are sobering. In the United States alone, the medical community projects approximately 42,670 deaths due to breast cancer in 2026. This equates to a staggering 117 lives lost every single day.
These numbers represent mothers, fathers, siblings, and friends. The overwhelming majority of these deaths are attributed to the progression of metastatic disease. Because the current standard of care—while life-extending—is not curative, the need for new, innovative research is absolute.
METAvivor, the primary beneficiary of the #LightUpMBC campaign, has carved out a unique and vital niche in the nonprofit landscape. Unlike many other organizations that divide their focus across the entire spectrum of breast cancer care and screening, METAvivor exclusively funds Stage 4 metastatic research. Their funding model is built upon a rigorous scientific peer-review process, combined with a patient advocate review board, ensuring that every dollar is funneled into projects with the highest potential to transform MBC from a terminal condition into a chronic, manageable, and survivable state.
Official Voices: The Faces Behind the Data
The human impact of this research is best articulated by those living within the community. Dr. Kelly Shanahan, Board President of METAvivor, describes her own journey as a living testament to the necessity of the organization’s work.
"When I was diagnosed with metastatic breast cancer in 2013, I certainly didn’t think I’d still be here 13 years later," Dr. Shanahan remarked. "My hope and the hope of so many others lies in research, and METAvivor-funded research is increasingly important these days. #LightUpMBC is the biggest contributor to this research and is also a way to bring us together as a community."
This sense of community is the driving force of the upcoming #LightUpMBC Live broadcast. Scheduled for Tuesday, October 13, at 8 p.m. ET (5 p.m. PT), the event will be hosted by Tami Eagle Bowling—herself an 11-year survivor of MBC—and Broadway star Kara Lindsay. The production is designed to be more than a telethon; it is a synthesis of advocacy and artistry, featuring:
- Patient Narratives: Raw, live stories shared from the sites of illuminated landmarks.
- Scientific Insights: Expert perspectives on the latest breakthroughs in MBC clinical trials.
- Artistic Tributes: Performances by Tony Award winners Victoria Clark and Dorian Harewood, alongside actress Christina Bianco and songwriter Cassandra Kubinski.
The Implications: Moving from Awareness to Action
The implications of the #LightUpMBC campaign extend far beyond the visual spectacle of glowing monuments. By forcing a global conversation on the specific, often hidden needs of the Stage 4 population, the organizers are actively challenging the status quo of cancer funding and awareness.
The primary objective of the campaign is to shift the narrative. For too long, public consciousness regarding breast cancer has been dominated by the "early detection saves lives" mantra. While essential, this messaging can inadvertently alienate those for whom early detection was not an option or for whom the disease has already progressed. #LightUpMBC insists that the "survivor" label must expand to include those whose survival is measured in months and years of ongoing treatment.
By participating in the campaign, the public is encouraged to take tangible action. Whether it is photographing a local landmark and sharing it on social media with the tags #LightUpMBC and #METAvivor, or contributing directly through the organization’s website, every action serves to bridge the funding gap.
With 100% of net proceeds from the campaign and the live stream directed toward research grants, the movement is effectively turning the light of awareness into the literal fuel for scientific progress. As Dr. Shanahan noted, the goal is not merely to shine a light on the disease, but to eventually see a future where that light no longer signals a terminal path, but a hopeful, extended journey.
For those interested in viewing the event or supporting the research, the full list of participating landmarks and donation portals can be accessed at www.lightupmbc.org. As the sun sets on October 13, the world will see that when it comes to metastatic breast cancer, the community remains undeterred, persistent, and, above all, luminous.
About the Author
